Telomir Pharmaceuticals, Inc. Common Stock (TELO)
USD 4.67
(-4.89%)
USD 4.67
(-4.89%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Operating Cash Flow | -3.85 Million | -468.66 Thousand | -119.39 Thousand |
| Net Income | -13.07 Million | -854.14 Thousand | -138.13 Thousand |
| Depreciation & Amortization | 1.61 Million | - | - |
| Deferred income taxes | - | - | - |
| Stock-based compensation | - | - | - |
| Change in working capital | 113.84 Thousand | 385.48 Thousand | 18.73 Thousand |
| Other non-cash items | 1.61 Million | -385.48 Thousand | -18.73 Thousand |
| Investing Cash Flow | - | - | - |
| Investments in PPE | -4.00 | - | - |
| Acquisitions | - | - | - |
| Investment purchases | - | - | - |
| Sales/Maturities of investments | - | - | - |
| Other Investing Activities | - | - | - |
| Financing Cash Flow | 3.85 Million | 470.08 Thousand | 119.39 Thousand |
| Debt repayment | -3.11 Million | -462.39 Thousand | - |
| Dividends payments | - | - | - |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | 1 Million | - | - |
| Other Financing Activities | -255.97 Thousand | 7689.00 | 119.39 Thousand |
| Accounts receivables | - | - | - |
| Accounts payables | 114.55 Thousand | 385.48 Thousand | 18.73 Thousand |
| Inventory | - | - | - |
| Other working capital | -713.00 | - | - |
| Cash at beginning of period | 1419.00 | - | - |
| Cash at end of period | 1231.00 | 1419.00 | - |
| Capital Expenditure | -4.00 | - | - |
| Effect of forex changes on cash | - | - | - |
| Net cash flow / Change in cash | -188.00 | 1419.00 | - |
| Free Cash Flow | -3.85 Million | -468.66 Thousand | -119.39 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.44 Million | -6.25 Million | -13.07 Million | -9.32 Million | -1.71 Million | -1.55 Million |
| Depreciation & Amortization | - | 4.33 Million | 1.61 Million | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -73.84 Thousand | -23.35 Thousand | 113.84 Thousand | 23 Thousand | -1.04 Million | 1.39 Million |
| Other non-cash items | 84.83 Thousand | 4.33 Million | 1.61 Million | 730.23 Thousand | 757.17 Thousand | 1516.81 |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 132.43 Thousand | 5.21 Million | 3.85 Million | 1.08 Million | 1.99 Million | 46.39 Thousand |
| Debt repayment | -132.43 Thousand | -101 Thousand | -3.11 Million | -1.06 Million | -2.14 Million | -93.34 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 5.83 Million | 1 Million | 90 Thousand | - | -90 Thousand |
| Other Financing Activities | 132.43 Thousand | -519.47 Thousand | -255.97 Thousand | -70.38 Thousand | -151.45 Thousand | 229.74 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -84.83 Thousand | 74.74 Thousand | 114.55 Thousand | 22.75 Thousand | -1.04 Million | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 10.99 Thousand | -98.09 Thousand | -713.00 | 250.00 | -963.00 | - |
| Cash at beginning of period | 3.27 Million | 1231.00 | 1419.00 | 2452.00 | 14.62 Thousand | 1807.00 |
| Cash at end of period | 1.88 Million | 3.27 Million | 1231.00 | 1231.00 | 2452.00 | 14.62 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.39 Million | 3.27 Million | -188.00 | -1221.00 | -12.17 Thousand | 12.82 Thousand |
| Free Cash Flow | -1.52 Million | -1.93 Million | -3.85 Million | -1.08 Million | -2 Million | -33.57 Thousand |
TIP
HUML
4310
NKLA
ROST
PZZA